Reproxalap is under clinical development by Aldeyra Therapeutics and currently in Pre-Registration for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData, Pre-Registration drugs for Keratoconjunctivitis Sicca (Dry Eye) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Reproxalap’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Reproxalap overview

Reproxalap (ADX-102) is under development for allergic conjunctivitis, dry eye syndrome and coronavirus disease 2019 (COVID-19). It is administered through oral, dermal and ophthalmic routes. It is developed based on pro-inflammatory reactive aldehyde species (RASP) scavenger platform. It is also under development for oral formulation indications including amino acid metabolism disorder including succinic semialdehyde dehydrogenase deficiency (SSADH) (oral formulation).

The drug candidate was also under development for the treatment of sjogren-larsson syndrome, discoid lupus erythematosus, congenital ichthyosis in subjects with dermatitis including contact dermatitis and allergic dermatitis, ocular inflammation including ocular rosacea with meibomian gland dysfunction, radiation-induced oral mucositis and acute non-infectious anterior uveitis.

Aldeyra Therapeutics overview

Aldeyra Therapeutics, is a biotechnology company. It offers treatment of immune-mediated diseases. The company offers product pipeline includes Reproxalap, an aldehyde trap for the treatment of allergic conjunctivitis and dry eye disease; ADX-2191 to treat proliferative vitreoretinopathy and intraocular lymphoma; and ADX-103/10X for the treatment of retinal disease. Aldeyra Therapeutics utilizes reactive aldehyde species (RASP), dihydrofolate reductase (DHFR) and chaperome (CHP) inhibition for advancing its pipeline products. The company’s drug candidates offer treatment for inflammation and genetic diseases caused by inborn errors of aldehyde metabolism. Aldeyra Therapeutics is headquartered in Lexington, Massachusetts, the US.

For a complete picture of Reproxalap’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.